Valneva shares gain 3% and are up 17.5% over the quarter

A rebound that places Valneva in the upper part of the SBF 120 index

Valneva shares gain 2.98% to €2.67 intraday, placing them among the strongest gainers in the SBF 120, which is up 1.04%. Over one week, the gain reaches 12.07%, while the stock still falls 27.15% over one year.

On November 10, the company released new data on its chikungunya vaccine: the seroresponse to Ixchiq is maintained at 94% five years after a single dose. This publication follows the one of November 9 on its shigellosis vaccine candidate, positive in phase 2, with next steps to be defined.

The share price moves back above its short-term moving averages, the MM200 remains far away

The share price is above the MM20 (€2.50, a gap of 6.60%) and the MM50 (€2.65, a gap of 0.57%), while it remains below the MM200 at €2.87, a gap of 7.14%.

The RSI at 57 reflects a bullish momentum without excess, and the resistance at €2.71 is only 1.7% away from the current price.

When it published its H1 2026 results on August 13, the group confirmed its outlook for the year, citing regulatory decisions expected within twelve months on its candidate against Lyme disease. Valneva will participate in the Jefferies Global Healthcare Conference on November 16.